These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38861372)

  • 1. Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial.
    Li L; Ivanova A
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38861372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isotonic design for single-arm biomarker stratified trials.
    Li L; Ivanova A
    Stat Methods Med Res; 2024 Jun; 33(6):945-952. PubMed ID: 38573793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations.
    Wheaton L; Jackson D; Bujkiewicz S
    Res Synth Methods; 2024 Jul; 15(4):543-560. PubMed ID: 38316618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confidence regions for treatment effects in subgroups in biomarker stratified designs.
    Wan F; Kunz CU; Jaki TF
    Biom J; 2019 Jan; 61(1):27-39. PubMed ID: 30474226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek.
    McShane LM; Rothmann MD; Fleming TR
    Clin Trials; 2023 Aug; 20(4):341-350. PubMed ID: 37095696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marker Sequential Test (MaST) design.
    Freidlin B; Korn EL; Gray R
    Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup identification from randomized clinical trial data.
    Foster JC; Taylor JM; Ruberg SJ
    Stat Med; 2011 Oct; 30(24):2867-80. PubMed ID: 21815180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratification and partial ascertainment of biomarker value in biomarker-driven clinical trials.
    Simon R
    J Biopharm Stat; 2014; 24(5):1011-21. PubMed ID: 24935478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.
    Beisel C; Benner A; Kunz C; Kopp-Schneider A
    Biom J; 2017 May; 59(3):511-530. PubMed ID: 28263395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the design and the analysis of stratified biomarker trials in the presence of measurement error.
    Halabi S; Lin CY; Liu A
    Stat Med; 2021 May; 40(12):2783-2799. PubMed ID: 33724513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternative method to analyse the biomarker-strategy design.
    Kunz CU; Jaki T; Stallard N
    Stat Med; 2018 Dec; 37(30):4636-4651. PubMed ID: 30260533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction.
    Habermehl C; Benner A; Kopp-Schneider A
    Biom J; 2018 Mar; 60(2):275-287. PubMed ID: 28762532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.